HLA-A and metastatic neoplasm: In contrast to B2M, there was no obvious trend for an altered frequency of HLA-A expression in metastatic diseases versus primary tumors (meta regression analysis Odds Ratio 1.16, CI 0.61-2.2, p-value ~ 0.65).